COPBLAM/MEVMP REGIMEN FOR INTERMEDIATE-GRADE NON-HODGKIN'S LYMPHOMA

Abstract

Thirty-six patients with intermediate-grade non-Hodgkin's lymphoma (NHL), ranging in age from 16 to 69 (median 52) years, were treated with cyclophosphamide, vincristine, prednisolone, bleomycin, doxorubicin, and procarbazine, followed by mitoxantrone, etoposide, vindesine, methotrexate with leucovorine rescue, and prednisolone (COPBLAM/MEVMP). Twenty-five patients (69%) achieved a complete remission (CR). The five-year survival rate and event-free survival rate (EFS) were 56% and 42%, respectively. A high survival rate was obtained in the low and low intermediate groups compared with the high and high intermediate groups (71%vs. 33%) according to the International Index. Major toxicities, which were dominant in the MEVMP regimen, were myelosuppression and stomatitis, but these were tolerable. COPBLAM/MEVMP seems to be an effective regimen for NHL.